{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Zhang F"],"pubmed_abstract":["Background
Ainuovirine (ANV) is a new-generation nonnucleoside reverse transcriptase inhibitor with potent antiviral activity and favorable neuropsychiatric and cardiometabolic safety. The SPRINT study showed that switching to fixed-dose ANV combined with lamivudine and tenofovir DF (ANV/3TC/TDF) provided non-inferior virologic efficacy and improved cardiometabolic conditions in virologically suppressed people living with HIV (PLWH) compared to that to cobicistat-boosted elvitegravir plus emtricitabine and tenofovir alafenamide (E/C/F/TAF) at 48 weeks.Methods
In the base study (weeks 0-48), eligible virologically suppressed PLWH (n = 762) were randomized to receive ANV/3TC/TDF or E/C/F/TAF in a double-blind manner. In the extensional study (weeks 48-96), eligible participan"],"journal":["BMC medicine"],"pagination":["524"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12482040"],"repository":["biostudies-literature"],"pubmed_title":["Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study."],"pmcid":["PMC12482040"],"pubmed_authors":["Ma P","Zhang F","Wang H","Wu H","Zhou Z","Wang M","He S","Lu H","Chen Z","Zhao Q","Yun X","Fu H","Qin H","Wei H","Chen Y","Cai W"],"additional_accession":[]},"is_claimable":false,"name":"Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study.","description":"Background
Ainuovirine (ANV) is a new-generation nonnucleoside reverse transcriptase inhibitor with potent antiviral activity and favorable neuropsychiatric and cardiometabolic safety. The SPRINT study showed that switching to fixed-dose ANV combined with lamivudine and tenofovir DF (ANV/3TC/TDF) provided non-inferior virologic efficacy and improved cardiometabolic conditions in virologically suppressed people living with HIV (PLWH) compared to that to cobicistat-boosted elvitegravir plus emtricitabine and tenofovir alafenamide (E/C/F/TAF) at 48 weeks.Methods
In the base study (weeks 0-48), eligible virologically suppressed PLWH (n = 762) were randomized to receive ANV/3TC/TDF or E/C/F/TAF in a double-blind manner. In the extensional study (weeks 48-96), eligible participan","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-04T01:38:08.39Z","creation":"2026-05-04T03:12:10.047Z"},"accession":"S-EPMC12482040","cross_references":{"pubmed":["41029679"],"doi":["10.1186/s12916-025-04376-5"]}}